Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Bone Marrow Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Hematopoietic and Lymphatic System Neoplasm
Bone Marrow Neoplasm

Cancer Family

Bone Marrow Neoplasm

CI-CAN-00000093Explore in graph →

Non-malignant1,034 active trials28 approved drugs633 evidence items

NCIt: C35370
MeSH: D019046

Overview
Statistics
Survival
Genomics18
Variants & evidence633
Drugs53
Trials4612
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (219)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 26–50 of 219 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.
· Oncotarget · 2011 · PMID 22081665 · validated civic_curation pubmed
High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.
· Blood · 2006 · PMID 16709929 · validated civic_curation pubmed
Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.
· Blood · 2006 · PMID 16384925 · validated civic_curation pubmed
Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.
· Blood · 2012 · PMID 22490330 · validated civic_curation pubmed
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.
· J Clin Oncol · 2012 · PMID 22291079 · validated civic_curation pubmed
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.
· Blood · 2008 · PMID 17957027 · validated civic_curation pubmed
Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.
· Leukemia · 2011 · PMID 21537333 · validated civic_curation pubmed

Showing 26–50 of 219 publications

← Previous
1
2
3
…
9
Next →

Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.

· Blood · 2009 · PMID 19221039 · validated civic_curation pubmed

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

· N Engl J Med · 2008 · PMID 18450602 · validated civic_curation pubmed

Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia.

· Blood · 2014 · PMID 24855211 · validated civic_curation pubmed

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.

· J Clin Oncol · 2010 · PMID 20026798 · validated civic_curation pubmed

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

· Blood · 2006 · PMID 16455956 · validated civic_curation pubmed

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

· J Natl Cancer Inst · 2008 · PMID 18230792 · validated civic_curation pubmed

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

· Blood · 2004 · PMID 14726387 · validated civic_curation pubmed

Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

· Cancer Res · 2001 · PMID 11585760 · validated civic_curation pubmed

FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.

· Blood · 2008 · PMID 17940205 · validated civic_curation pubmed

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.

· Haematologica · 2010 · PMID 20494930 · validated civic_curation pubmed

RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.

· J Clin Oncol · 2011 · PMID 21343560 · validated civic_curation pubmed

TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.

· J Clin Oncol · 2012 · PMID 22430270 · validated civic_curation pubmed

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

· Blood · 2009 · PMID 19666869 · validated civic_curation pubmed

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

· J Clin Oncol · 2011 · PMID 21343549 · validated civic_curation pubmed

TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.

· Blood · 2011 · PMID 21828143 · validated civic_curation pubmed

ASXL1 mutations define a subgroup of patients with acute myeloid leukemia with distinct gene expression profile and poor prognosis: a meta-analysis of 3311 adult patients with acute myeloid leukemia.

· Leuk Lymphoma · 2015 · PMID 25308295 · validated civic_curation pubmed

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.

· Blood · 2009 · PMID 19304957 · validated civic_curation pubmed

Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.

· Blood Cancer J · 2014 · PMID 25014773 · validated civic_curation pubmed